// App-Quantinova.ai

Tu1101 : IMPACT OF TIME INTERVAL BETWEEN THE SECOND DOSE OF A SPLIT-DOSE REGIMEN OF NER1006 VERSUS TRISULFATE AND START OF COLONOSCOPY: EVALUATION OF COLON CLEANSING RATES

Researchers

Presenter

  • Michael Epstein

Principal Investigators

  • Zeev Heimanson

  • Bharat Amlani

Medical Centers

  • Digestive Disorders Associates, Annapolis, MD

  • Salix Pharmaceuticals, Bridgewater, NJ, USA,

  • Norgine Ltd, Harefield, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Ophthalmology (OP)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • NER1006

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Non Inferiority

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved